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Abstract
Objectives. To outline rationale and potential strategies for rheumatology experts to be able to develop
disease-specific Core Sets under the framework of the International Classification of Functioning, Disability
and Health (ICF). ICF is a universal framework introduced by the World Health Organization (WHO) to
describe and quantify the impact and burden on functioning of health conditions associated with impair-
ment/disability.
Methods. A combined effort of the EULAR Scleroderma Clinical Trial and Research and the ICF Research
Branch was initiated to develop an ICF language for scleroderma. From our Medline literature review,
using the abbreviation and spelled out version of ICF, we assembled approaches and methodological
reasoning for steps of core set development.
Results. The ICF can be used for patient care and policy-making, as well as the provision of resources,
services and funding. The ICF is used on institutional, regional, national and global levels. Several diseases
now have ICF Core Sets. Patients with complex rheumatologic diseases will benefit from a disease-
specific ICF Core Set and should be included in all stages of development. ICF Core Set development
for rheumatic diseases can be conducted from a number of feasible strategies.
Conclusion. This overview should help to clarify useful processes leading to development of an ICF Core
Set, and also provide a platform for expert groups considering such an endeavour.
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The International Classification of
Functioning, Disability and Health
The International Classification of Functioning, Disability
and Health (ICF) is a universal framework introduced by
the World Health Organization (WHO) to describe and
quantify the impact of impairment caused by health con-
ditions on functioning, which may lead to disability. The
ICF is a common idiom across diseases, health profes-
sionals and policy-makers, which uses a standardized
alphanumerical language. The ICF is accepted by national
and international health-care and policy-making systems
to assess the impact of disease on personal, scientific,
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economic and service levels. It is devised to be a fair rep-
resentation of disability and impairment of functioning that
is consistent and comparable across gender, socio-
economic, geographic, cultural, gender and disease
parameters.
The ICF is used or being initiated in some capacity in
71 countries, including Argentina, Australia, France,
Germany, Ireland, Italy, Japan, Malawi, Mexico,
Netherlands, Sweden, Switzerland and Zimbabwe; 191
WHO member states in 2002 have agreed to adopt ICF
for scientific standardization of disability data [1, 2].
Diseases linked to the ICF include RA, AS, IBD, OA,
osteoporosis, back pain, diabetes, ischaemic heart dis-
ease, chronic obstructive pulmonary disease, obesity,
stroke, multiple sclerosis, spinal cord injury, traumatic
brain injury, GuillainBarre, myasthenia gravis, sleep dis-
orders, depression, chronic widespread pain, breast
cancer and head and neck cancer.
The ICF is based on the biopsychosocial model that
takes into account the impact of disease beyond the trad-
itional model of health in terms of the pathophysiological
biological model of disease within the biological confines
of the patient [3]. The biopsychosocial model describes
the health experience of the whole person in relation to
their disease state, the effects of disease on the body and
the impact of disease on important aspects of living in
society and on the patient’s interactions with their envir-
onment. It departs from the traditional biological model of
health, in that beyond the concepts of how a disease
changes the body’s structure and the body’s ability to
function on a molecular, histological or anatomical level,
the biopsychosocial model of health recognizes that in-
trinsic to the measurement of disease is the environment
within which the patient operates. It recognizes that
real-life operationalizes impairment, limitations or restric-
tions. It is at this juncture that disability or functioning is
truly defined. Additionally, just as health status effects the
host’s interaction with their environment, so the environ-
ment affects the health outcomes and status of the host. A
good example of this would be a severe mobility impair-
ment resulting in complete reliance on a wheelchair—re-
stricting one’s ability to participate in work if there are no
accommodations for entry into the workplace. However, a
positive life effect on remunerative and self-esteem as-
pects would result if the environment facilitated entry
into the workplace. This positive life effect is likely to
have an overall positive effect on the individual’s health
and participation in society. The ICF strives to capture and
quantify the burden associated with the disease in all the
essential functioning aspects of a patient’s life.
Implications for rheumatic diseases
Functioning is an essential consideration in chronic illness.
The development of disease-specific core sets for com-
plex rheumatic diseases that are based in the language of
the ICF potentially ensures fair representation of the
burden of these diseases on global and regional stages.
If core set development is conducted by the disease
experts themselves—meaning patients as well as
physicians, rehabilitation specialists and specialist
nurses with a dedicated expertise in the particular dis-
ease—one would expect a more accurate ICF language
for a specific disease. The ability to describe the burden of
disease within the context of the ICF creates a quantifiable
argument for funding and allocation of resources in regard
to research, provision of patient services as well as having
potential effects on government and insurance policies
that affect patients with chronic rheumatic diseases.
Mechanics of ICF
A note of clarification: the ICF is different from the WHO
International Classification of Diseases, which names the
disease or condition (for example, the International
Classification of Diseases code for RA is 714.0). The ICF
describes the type and degree of various functioning im-
pairments, limitations and restrictions related to or asso-
ciated with a condition.
Parts
The ICF is broken down into two main parts (Fig. 1) that
have several components. There are 1454 classifications
housed hierarchically under these components.
The first part (i.e. functioning) is composed of three
components: body structure (s), which is related to anat-
omy; body function (b), which refers to the physiological
and psychological functions of the body; and activities
and participation (d), whereby activities are tasks or ac-
tions with a goal and participation is activity placed within
contextual meaning such as social, family, work, etc.
The second part is currently composed of two compo-
nents: environmental factors (e), which allows for
recording the positive or negative influence of the envir-
onment (e.g. assistive devices, access to care, climate,
etc.) on functioning; and personal factors (pf), which are
personal characteristics of the individual. These are not
yet classified (i.e. coded) in the ICF at this time.
Classification hierarchy
At the first level of classification are chapters, followed by
second, third and fourth levels (Table 1), when available.
Chapters are the broadest headings relevant to a com-
ponent. The chapters pertaining to body structure (s) and
body function (b) relate to body systems. The chapters for
body structure and body function are parallel to each
other for ease of use. For example, chapter 6 for compo-
nents s6 and b6 relates to the genitourinary and repro-
ductive systems and functions.
Under the chapters come the second level of classifi-
cations that comprise subheadings that deconstruct a
chapter to its basic elements. Most ICF Core Sets are
developed to this second level of classification.
However, there is no rule as such. Beneath the second
level is the third level of classifications that confers detail
to the second-level manifestations. The third level at-
tempts to capture a further level of detail of the patient
experience. An example for dysphagia would be b51052,
where b5 is the body functions chapter, Functions of the
digestive, metabolic and endocrine systems; b510 is the
second-level classification of Ingestion functions; b5105 is
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the third level of Swallowing and b51052 is the more de-
tailed classification of Esophageal swallowing. One can
interact with the ICF hierarchy at http://apps.who.int/clas-
sifications/icfbrowser/.
Recording impairment
Regarding utility, the ICF framework is flexible. It provides
a vehicle for answering a wide range of questions invol-
ving clinical use, research and policy-making that can be
easily understood among professional disciplines. The ICF
uses a five-point qualifier for the scale of impairment in
addition to classifications that comfortably and meaning-
fully translate visual analogue or percentage scales. Such
a five-point scale is well suited also to gauge change over
time for purposes of research and clinical care. For ex-
ample, severe impairment of oesophageal swallowing can
be described as b51052.4, where 4 indicates a level of
complete impairment on a scale of 04 (0 = no impairment,
1 = mild impairment, 2 = moderate impairment, 3 = severe
impairment, 4 = complete impairment).
ICF Core Sets
It has been generally accepted for diseases (or groups
of similar disorders) that it is worthwhile to collate a
comprehensive core set of ICF categories for use in multi-
disciplinary assessments of patients. Although most ICF
Core Sets develop categories only to the second level of
classification, there is no rule for this. Comprehensive core
sets are usually composed of a large number of items and
so are not always feasible for daily clinical use. For this
reason, there is often a brief core set generated, which is
an abbreviated list of the minimum relevant ICF categories
for use in a targeted clinical setting or research setting [4].
A brief ICF Core Set is based on the larger comprehensive
ICF Core Set. Core sets have in the past been derived in a
FIG. 1 Interactions between domains of ICF in relation to the health condition.
Adapted from the ICF’s Towards a Common Language of Functioning, Disability and Health (Geneva, Switzerland: WHO,
2002).
TABLE 1 A hierarchy of visual impairment
Level Example Coding
Chapter Chapter 2: Sensory functions and pain b2
Second level Seeing functions b210
Third level Quality of vision b2102
Fourth level Colour vision b21021
Reproduced from the ICF’s Towards a Common Language of Functioning, Disability and Health (Geneva, Switzerland:
WHO, 2002), http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf (30 May 2012, date last accessed), with
permission.
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multi-step approach, which, in the earlier history of core
set development, did not incorporate patients’ insights [5].
Careful consideration in planning the core set method-
ology ensures that appropriate structure and strategies
are used for the particular disease in question. In the pre-
liminary steps, it is important to obtain the broadest col-
lection of disease descriptors before proceeding with
strategies to reduce the collection into the comprehensive
and brief core sets:
Item collection  Continued item collection with
opportunity for item reduction Item reduction
The goals of methodology and examples of strategies
that have been used to accomplish core set development
are outlined as follows.
Item collection
The development of comprehensive core sets usually
begins with exercises to identify qualities and ICF cate-
gories related to the disease in question. This involves
combinations of methods to collect a group of qualities
associated with a disease. In the early history of core set
development [6], central to this collection was a literature
review to identify relevant outcome measures,
item-generating discussions and Delphi exercises (see
below) with health-care professionals, as well as applica-
tion of a formal ICF checklist [7, 8], or a review of medical
data in a cross-sectional convenience sample of patients
[9] for generating categories that were typical, relevant
and frequent in patients with a specific disease. This
item collection (authors’ term) phase was later modified
by some efforts to include patients in focus groups and/or
Delphi exercises [10] as well as augmenting the role of
allied health professionals [11]. This list of qualities that
is generated is then linked to the ICF usually by two re-
viewers who are health professionals and familiar with ICF
linkage rules [12].
Content and face validation
Traditionally the core set has been selected from this col-
lection of ICF codes (with their descriptors) by health pro-
fessionals (1630 participants), using group consensus
exercises to select codes that are relevant and typical
for the disease. The types of consensus techniques for
these processes are typically not described in the litera-
ture other than noting that some efforts included plenary
and break-out sessions. The codes may also undergo a
similar process through a Delphi consensus process
(using a three-step voting survey) that most commonly
includes health professionals. The Delphi exercises have
traditionally used a two-point Likert scale (yes/no) an-
chored in relevant or typical of the health condition.
Delphi exercises usually include the ability to add items
that the participant perceives are missing. Face and con-
tent validity may also be sought from specific groups (pa-
tients, nurses, rehabilitation therapists or physicians) [11,
13] that may possess a specific perspective on the dis-
ease or may have been missed in the earlier processes of
the core set’s development. This is most commonly done
using a Delphi exercise.
Construct validation
Testing of the core set in real-life situations provides in-
sight into which components of the core set have con-
struct validity. Cross-sectional studies can assist in this
and might use any number of strategies: several serial
surveys to track patient-reported perspectives that
assess the disease state over time [14], or application of
the core set in clinical settings, such as rehabilitation facil-
ities, out-patient health centres, etc., to test the real-life
utility of the core set. This process may ultimately reveal
the need for further item reduction or augmentation.
ICF Core Set for RA: an example
The core set development for RA [5, 15] was one of the
first 12 diseases undertaken in an en masse effort that
began with a three-pronged strategy in the collection of
qualities: (i) a Delphi exercise including health profes-
sionals whose level of expertise in RA was not described;
(ii) a literature review of clinical trials in RA published from
1991 to 2000 to identify outcome measures relevant to
RA; and (iii) data collection from cross-sectional conveni-
ence samples of RA patients by chart review and interview
were applied against the ICF checklist of 125 ICF cate-
gories identified as being important in chronic diseases in
order to assess which categories are relevant to RA. The
items from each step were linked to the ICF by two re-
viewers. From this, a set of 530 ICF categories were gen-
erated at the second, third and fourth levels.
From here, a comprehensive RA core set of 96 cate-
gories on the second, third and fourth levels was decided
upon with an undescribed formal decision-making pro-
cess employing 17 experts not including patients. The
level of expertise in RA was not reported, with half of
the physicians being non-rheumatologists, but was
described as at least a specialization in physical medicine,
with one each of a nurse, an occupational therapist and a
physiotherapist, with conflicting information regarding the
number of countries represented: both 8 and 12 countries
are stated. At the same meeting, experts voted, and items
receiving a 50% majority were included in the brief RA
core set that yielded 39 second-level categories. The
comprehensive RA Core Set was then validated from a
nurse’s perspective and then by physicians in two separ-
ate Delphi exercises [11, 13].
The ICF Core Sets for RA has not been validated
against commonly used measures in RA, such as the
HAQ; however, Core Sets have been compared with
regard to the collection of concepts (or ICF categories)
held within validated and commonly used outcome meas-
ures [16]. Developing new outcome measures to replace
currently used measures is not the purpose of an ICF Core
Set. Rather an ICF Core Set should present, at a min-
imum, the disease experience and all relevant areas of
disability (e.g. interference with engagement in life
areas). In so doing, the ICF Core Set (due to its broad
attempt to collect items) is bound to contain important
disease concepts not contained within the most com-
monly used measures. If, over time, it is perceived that
categories not currently reflected within validated
www.rheumatology.oxfordjournals.org 2173
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instruments prove to be important to patients or demon-
strate high discriminatory properties, it makes sense to
consider modification of currently used measures or the
introduction of new measures. Although the process of
ICF Core Set development may provide a vehicle to iden-
tify areas of omission in a current assembly of outcome
measures (please see the section on Health Index
Development), a Core Set is not intended to replace vali-
dated instruments. ICF categories tend to be broad or
lack granularity in description, and as such may provide
a practical approach that is useful where the detail of in-
struments such as HAQ or the Short Form-36 may not be
helpful in certain settings or have an incomplete descrip-
tion of the disease experience.
Health index development
One of the more intricate strategies exploring the use of
ICF in rheumatic disease is an effort in progress for AS [14,
17]. Current outcome measures for AS were perceived to
be insufficient in the assessment of disease activity, which
inspired these experts (with patient partners) to push
beyond the development of core sets and strive to develop
a health index in AS using the ICF. This effort is intended to
result in a new instrument that will comprise both validated
AS assessment methods as well as previously unrecog-
nized components of the AS health experience.
Limitations of the ICF
Unresolved limitations of the ICF exist. The ICF is a broad
description of disability and functioning and therefore may
be unable to correlate well with the very specific items and
interrelated concepts of commonly used measures in spe-
cific diseases. Yet, the very specific measures that are
used may not be congruent with what is needed in dis-
ability data to quantify the true impact of an illness across
broad categories in such an accessible way. Additionally,
though the ICF provides significant utility in systems (e.g.
health information technology, electronic health records)
that have adopted the framework, it has limited utility in
systems that have not pro-actively adopted it. True adop-
tion requires training and familiarity with the ICF. In add-
ition to the limitation to broad concepts of functioning, the
ICF categories are discrete and do not interrelate or form
associations in a straightforward manner with other cate-
gories. For example, the cause of one’s inability to comb
one’s hair is not discernible from muscle weakness, pain-
ful arthritis or breathlessness in a patient with
anti-synthetase syndrome, in which muscle, joint and
lung involvement are all potential disease manifestations.
Although there has been a commitment by the WHO
member states to incorporate the ICF as a scientific
basis and platform through which disability data will be col-
lected, it is currently used by 71 WHO member countries,
which is less than half of the WHO assembly that agreed to
adopt the ICF framework. However, that might be consid-
ered significant enough to be worthwhile [2]. But this initial
enthusiasm to adopt without subsequent initiation may
speak to the lack of either preparedness, ease or re-
sources for implementation.
EUSTAR initiative to develop an ICF Core
Set for SSc
The EULAR Scleroderma Clinical Trial and Research
(EUSTAR) has emerged from an international SSc registry
that has precipitated important key concepts to our cur-
rent understanding of SSc into a forum and network for
many different research activities in SSc with the potential
for improved health outcomes for patients with SSc. For
the ICF approach described herein, EUSTAR provides the
framework for access to international medical and health
experts, distribution of the final products as well as po-
tential examination of the identified ICF categories to fur-
thering SSc subgroup identification.
Planned steps towards the development of an ICF Core
Set for SSc are as follows:
(i) Gain support and involvement of key SSc patients
and scientific organizations.
(ii) Medical and Patient Expert Initial Data
Collection—Focus Groups:
(a) Using both open-ended and task-centred stra-
tegies to elicit information.
(b) Broad international representation.
(c) Broadpatientexpert inclusion reflecting thespec-
trum of disease involvement, severity and stage.
(d) Medical experts include physicians, physiother-
apists, occupational therapist, specialty nurses
and social workers with clearly defined and
recognized expertise in SSc.
(e) Medical expert involvement must include repre-
sentation of focal expertise in SSc manifest-
ations such as RP, ulcers, wound care,
cardiac manifestations, pulmonary hyperten-
sion, pulmonary fibrosis, musculoskeletal,
sexual function and health-related quality of life.
(iii) Linkage of instruments validated in SSc:
(a) Through systematic literature review, identify all
instruments validated at any level in SSc.
(b) Deconstruct each item of each instrument into
its most basic concepts per linking rules [12].
(c) Linkage of deconstructed items of each instru-
ment by two health professionals proficient in
ICF (one a physiotherapist and another a
rheumatologist with expertise in SSc).
(d) Interlinker agreement must be >70% concord-
ance; otherwise a third linker is introduced.
(iv) Pooling of data from focus groups and instruments.
(v) Item reduction and content validation:
(a) Online survey is to be distributed in several lan-
guages for medical and patient experts with a
Likert scale anchored in whether the item is
important or typical to the SSc experience.
The survey will have the ability to provide any
aspects that the participant feels might be
missing.
(b) Plenary and small group evaluations with med-
ical and patient experts of post-survey items is
to be identified in both the Comprehensive and
Brief Core Sets.
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(vi) Report of the Comprehensive and Brief Core Sets.
(vii) Construct validation via the following strategies:
(a) Serial observation using the Core Set in a clin-
ical setting.
(b) Serial e-mail surveys to patients to assess per-
ceived changes over time.
The aforementioned construct validation strategies are
planned for assessment on a five-point scale (no impair-
ment to complete impairment), with like items correlated
against commonly used instruments.
The project leaders are keenly aware of issues concern-
ing the complexity and multi-organ system nature of SSc
as being novel to the ICF. We are committed to remaining
receptive to and accommodating an end-structure that
will ensure optimal utility. A key challenge will be in mana-
ging efficiently an atypically high number of identified
categories. This is likely to require unique approaches.
For example, SSc may require several domain-based
Core Sets to ensure high utility and broad application.
Another predicted challenge, which also may be an-
swered by an organ-based Core Set, is that the ICF cur-
rently does not facilitate interrelationships of categories.
For example, anxiety that may be the result of dealing with
the stress of incontinence will appear as two distinct un-
associated categories without an association that would
tie the two together such that if the incontinence were not
a prominent feature, anxiety might potentially also recede.
Points to consider for ICF Core Set
development in SSc and other
rheumatic diseases
ICF Core Sets for RA, osteoporosis, OA, chronic wide-
spread pain and low back pain were initiated in the first
group of 12 chronic diseases. These core sets were de-
veloped in an en masse effort [5]. Although these initiatives
were productive and an important step forward, there are
many more complex diseases that require accurate ICF
representation. For example, there have not been core
sets developed for complex multi-organ system diseases
such as vasculitis or SSc.
EUSTAR and the ICF Research Branch of the WHO
Collaboration Centre of the Family of International
Classifications in Germany (DIMDI) are working towards
the development of an ICF language for systemic scler-
osis [18]. Previous papers describing the process of ICF
development of core sets have provided results of the
development, but somewhat limited details of the process
itself. However, we would like to emphasize the import-
ance of a pre-defined methodology, clearly stated vali-
dated consensus techniques and clarification of the
objectives behind varied methods that have lead to core
set development. This would empower the selection or
development of unique strategies that are appropriate
for ICF Core Set development for future diseases.
Early core set projects engaged mostly physicians and
the resulting publications do not specify the degree
of expertise for a particular disease. We feel that ICF
Core Set development of complex diseases needs
careful attention beyond general specialists, but rather
subspecialists with a dedicated expertise in the disease
in question. For example, it would not be enough to
engage general rheumatologists, general rehabilitation ex-
perts or nurses in scleroderma ICF Core Set development.
A complex disease such as SSc deserves the attention
of sclerodermologists, i.e. health care professionals with
demonstrated expertise in scleroderma. These important
details should be clearly stated in publications.
In rheumatic diseases, it is important to include patients
in the processes leading to ICF Core Set development. If
patients are included, aspects of the health experience
often overlooked by health care professionals are likely
to be identified [1921]. Therefore the strength of the pro-
cess is enhanced by including patient experts at each
validation and decision-making step. We advocate that
at least one patient expert contribute to the design and
implementation of the methodology [18]. Along the same
vein, there should be as equal representation as possible
of patients, rehabilitation specialists, specialist nurses and
physicians in each step of the process supported by inter-
national and cultural diversity.
In summary, the development of ICF Core Sets for
rheumatic diseases is important for patient care and pa-
tient advocacy so as to ensure fair representation and
allocation of resources. Disease-specific ICF Core Set de-
velopment for complex rheumatic diseases is a tangible
and practicable endeavour that is best informed by true
experts of the disease in question, namely patients,
rehabilitation and nurse specialists and physicians. We an-
ticipate that the challenges faced and the model presented
in the development of an ICF Core Set for SSc will be useful
in the development of ICF Core Sets for other complex
multi-organ system diseases, inclusive of vasculitis and
SLE.
Rheumatology key messages
. Multi-level functioning in chronic illnesses, including
complex rheumatic diseases, is important in
health-care delivery.
. The WHO’s ICF standardizes disability data for use
at individual, institutional, national and international
levels.
. ICF Core Set development for rheumatic diseases
is feasible and can be conducted by several
strategies.
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